0001140361-16-079730.txt : 20160914 0001140361-16-079730.hdr.sgml : 20160914 20160914093536 ACCESSION NUMBER: 0001140361-16-079730 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160914 DATE AS OF CHANGE: 20160914 EFFECTIVENESS DATE: 20160914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HDL THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001569047 IRS NUMBER: 273015978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-270577 FILM NUMBER: 161884318 BUSINESS ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 BUSINESS PHONE: 772-453-2770 MAIL ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 D 1 primary_doc.xml X0707 D LIVE 0001569047 HDL THERAPEUTICS, INC. 601 21st Street Suite 300 Vero Beach FL FLORIDA 32960 772-453-2770 DELAWARE None None Corporation true 2013 Michael Matin c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Director Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Bryan Brewer c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Director Dr. Brewer is the Chief Scientific Officer of the Issuer. Biotechnology Decline to Disclose 06b false 2016-08-05 true true true Series C Preferred Stock false 0 15000000 1486610 13513390 true 0 13 0 0 400000 true The gross proceeds from the offering will be used for working capital, some of which will be used to pay the salaries of related persons named in Item 3. false HDL THERAPEUTICS, INC. /s/ Michael Matin Michael Matin Chief Executive Officer of the Issuer 2016-09-14